This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

Archeus hopes to begin a Phase I trial of the PSMA-targeted agent in metastatic, castration-resistant prostate cancer later this year.

HeartBeam (NASDAQ: BEAT) announced it has received FDA 510(k) clearance for its flagship ECG system, a first-of-its-kind, credi ...

Ambu has received expanded FDA 510(k) clearance for its aScope 5 Cysto HD, making it the first single-use flexible ...

Sacroiliac joint fusion technology is advancing, and the data shows it’s efficacy across different medtech companies. Five notes: 1. Tenon Medical earned FDA 510(k) clearance to use its Catamaran ...

Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia - - Also ...

HeartBeam (NASDAQ: BEAT) announced it has received FDA 510(k) clearance for its flagship ECG system, a first-of-its-kind, ...

Sacroiliac joint fusion technology is advancing, and the data shows it’s efficacy across different medtech companies. Five notes: 1. Tenon Medical earned FDA 510(k) clearance to use its Catamaran ...

According to Exo, the AI apps for its ultrasound device to detect two common lung conditions are the first of their kind to ...

CeQur announced today that it reached the milestone of 10 million mealtime insulin injections replaced with its Simplicity ...